# EQ/T.Rowe Price Health Sciences Portfolio

EQ/T.Rowe Price Health Sciences Portfolio is a registered fund series of EQ Advisors Trust (series S000062644). Net assets $159.0M as of 2026-03-31.

## Profile

- Series ID: S000062644
- Registrant: EQ Advisors Trust
- LEI: 549300NXA7ED0U1K6106
- Net assets: $159.0M
- Total assets: $160.7M
- As of: 2026-03-31

## Advisers

- [T. ROWE PRICE ASSOCIATES, INC. (Subadvisor)](https://search.stillhousedata.com/firm/105496)
- [Equitable Investment Management Group, LLC (Advisor)](https://search.stillhousedata.com/firm/156933)

## Top holdings (179 reported)

_Showing 15 of 179 holdings by value._

| Holding | Ticker | Value | % of fund |
| --- | --- | --- | --- |
| [Eli Lilly & Co.](https://search.stillhousedata.com/security/532457108) | — | $16.2M | 1019.54% |
| [Thermo Fisher Scientific, Inc.](https://search.stillhousedata.com/security/883556102) | — | $6.6M | 412.66% |
| [Intuitive Surgical, Inc.](https://search.stillhousedata.com/security/46120E602) | — | $5.9M | 371.07% |
| [Stryker Corp.](https://search.stillhousedata.com/security/863667101) | — | $5.6M | 353.34% |
| [Merck & Co., Inc.](https://search.stillhousedata.com/security/58933Y105) | — | $5.5M | 348.07% |
| AstraZeneca plc | — | $5.1M | 320.82% |
| [UnitedHealth Group, Inc.](https://search.stillhousedata.com/security/91324P102) | — | $5.0M | 311.45% |
| [Argenx SE](https://search.stillhousedata.com/security/04016X101) | — | $4.8M | 303.89% |
| [AbbVie, Inc.](https://search.stillhousedata.com/security/00287Y109) | — | $4.6M | 291.04% |
| [Regeneron Pharmaceuticals, Inc.](https://search.stillhousedata.com/security/75886F107) | — | $4.3M | 271.37% |
| [Gilead Sciences, Inc.](https://search.stillhousedata.com/security/375558103) | — | $4.2M | 266.87% |
| [Johnson & Johnson](https://search.stillhousedata.com/security/478160104) | — | $3.9M | 248.12% |
| [Vertex Pharmaceuticals, Inc.](https://search.stillhousedata.com/security/92532F100) | — | $3.9M | 247.32% |
| [Danaher Corp.](https://search.stillhousedata.com/security/235851102) | — | $3.3M | 208.24% |
| [Alnylam Pharmaceuticals, Inc.](https://search.stillhousedata.com/security/02043Q107) | — | $2.7M | 168.52% |

## Net asset history

| Report date | Net assets |
| --- | --- |
| 2026-03-31 | $159.0M |
| 2025-12-31 | $176.2M |
| 2025-09-30 | $158.1M |
| 2025-06-30 | $152.8M |
| 2025-03-31 | $159.9M |
| 2024-12-31 | $164.3M |
| 2024-09-30 | $188.7M |
| 2024-06-30 | $185.1M |

## More

- [Registrant: EQ Advisors Trust](https://search.stillhousedata.com/registrant/1027263)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/fund/S000062644.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.